These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 17395135)

  • 1. The therapy of congenital myasthenic syndromes.
    Engel AG
    Neurotherapeutics; 2007 Apr; 4(2):252-7. PubMed ID: 17395135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Congenital myasthenic syndromes: phenotypic expression and pathophysiological characterisation].
    Andreux F; Hantaï D; Eymard B
    Rev Neurol (Paris); 2004 Feb; 160(2):163-76. PubMed ID: 15034473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic strategies for congenital myasthenic syndromes.
    Lee M; Beeson D; Palace J
    Ann N Y Acad Sci; 2018 Jan; 1412(1):129-136. PubMed ID: 29381222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Congenital myasthenic syndromes: spotlight on genetic defects of neuromuscular transmission.
    Müller JS; Mihaylova V; Abicht A; Lochmüller H
    Expert Rev Mol Med; 2007 Aug; 9(22):1-20. PubMed ID: 17686188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic strategies in congenital myasthenic syndromes.
    Schara U; Lochmüller H
    Neurotherapeutics; 2008 Oct; 5(4):542-7. PubMed ID: 19019305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Congenital myasthenic syndromes.
    Finsterer J
    Orphanet J Rare Dis; 2019 Feb; 14(1):57. PubMed ID: 30808424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Congenital myasthenic syndromes with kinetic abnormalities of the acetylcholine receptor].
    Islam Kediha M; Tazir M; Sternberg D; Eymard B; Ali Pacha L
    Med Sci (Paris); 2023 Nov; 39 Hors série n° 1():58-63. PubMed ID: 37975772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome.
    Chaouch A; Müller JS; Guergueltcheva V; Dusl M; Schara U; Rakocević-Stojanović V; Lindberg C; Scola RH; Werneck LC; Colomer J; Nascimento A; Vilchez JJ; Muelas N; Argov Z; Abicht A; Lochmüller H
    J Neurol; 2012 Mar; 259(3):474-81. PubMed ID: 21822932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Pathologic Features of Congenital Myasthenic Syndromes Caused by 35 Genes-A Comprehensive Review.
    Ohno K; Ohkawara B; Shen XM; Selcen D; Engel AG
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Congenital myasthenic syndromes: current diagnostic and therapeutic approaches.
    Schara U; Della Marina A; Abicht A
    Neuropediatrics; 2012 Aug; 43(4):184-93. PubMed ID: 22911480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of the congenital myasthenic syndromes.
    Engel AG
    Neuromuscul Disord; 2012 Feb; 22(2):99-111. PubMed ID: 22104196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoxetine prevents acetylcholine-induced excitotoxicity blocking human endplate acetylcholine receptor.
    Deflorio C; Catalano M; Fucile S; Limatola C; Grassi F
    Muscle Nerve; 2014 Jan; 49(1):90-7. PubMed ID: 23559277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure.
    Vanhaesebrouck AE; Webster R; Maxwell S; Rodriguez Cruz PM; Cossins J; Wickens J; Liu WW; Cetin H; Cheung J; Ramjattan H; Palace J; Beeson D
    Brain; 2019 Dec; 142(12):3713-3727. PubMed ID: 31633155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The spectrum of congenital myasthenic syndromes.
    Engel AG; Ohno K; Sine SM
    Mol Neurobiol; 2002; 26(2-3):347-67. PubMed ID: 12428764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Congenital myasthenic syndromes in childhood: Drug therapeutic strategies].
    de la Vaissière S; Toutain A; Chêne MA; Lagrue E; Cantagrel S; Provost S; Eymard B; Castelnau P
    Arch Pediatr; 2015 Jul; 22(7):724-8. PubMed ID: 26028221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Congenital myasthenic syndromes: difficulties in the diagnosis, course and prognosis, and therapy--The French National Congenital Myasthenic Syndrome Network experience].
    Eymard B; Stojkovic T; Sternberg D; Richard P; Nicole S; Fournier E; Béhin A; Laforêt P; Servais L; Romero N; Fardeau M; Hantaï D;
    Rev Neurol (Paris); 2013 Feb; 169 Suppl 1():S45-55. PubMed ID: 23452772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Congenital myasthenic syndromes in 2012.
    Engel AG
    Curr Neurol Neurosci Rep; 2012 Feb; 12(1):92-101. PubMed ID: 21997714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic heterogeneity and pathophysiological mechanisms in congenital myasthenic syndromes.
    Barišić N; Chaouch A; Müller JS; Lochmüller H
    Eur J Paediatr Neurol; 2011 May; 15(3):189-96. PubMed ID: 21498094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Congenital myasthenic syndromes and the formation of the neuromuscular junction.
    Beeson D; Webster R; Cossins J; Lashley D; Spearman H; Maxwell S; Slater CR; Newsom-Davis J; Palace J; Vincent A
    Ann N Y Acad Sci; 2008; 1132():99-103. PubMed ID: 18567858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Congenital myasthenic syndromes: A diverse array of molecular targets.
    Engel AG; Ohno K; Sine SM
    J Neurocytol; 2003; 32(5-8):1017-37. PubMed ID: 15034283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.